Article Images
Content deleted Content added
m |
m |
||
Line 40: == mTOR inhibitors as therapies == <!-- target of MTOR inhibitor --> mTOR inhibitors, e.g. [[rapamycin]], are already used to prevent [[transplant rejection]]. Rapamycin is also related to the therapeuty of glycogen storage disease (GSD).Some articles reported that rapamycin can inhibit mTORC1 so that the phosphorylation of GS(glycogen storage) can be increased in skeletal muscle.This discovery represents a potential novel therapeutic approach for glycogen storage diseases that involve glycogen accumulation in muscle.<ref name="pmid20554235">{{cite journal | author = Ashe KM, Taylor KM, Chu Q, Meyers E, Ellis A, Jingozyan V, Klinger K, Finn PF, Cooper CG, Chuang WL, Marshall J, McPherson JM, Mattaliano RJ, Cheng SH, Scheule RK, Moreland RJ | title = [http://www.selleckchem.com/downloads/Deforolimus&Temsirolimus(Molecular_Genetics_and_Metabolism_May_5_2010).pdf Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease] | journal = Mol. Genet. Metab. | volume = 100 | issue = 4 | pages = 309–15 | year = 2010 | month = August | pmid = 20554235 | doi = 10.1016/j.ymgme.2010.05.001 }}</ref> Various natural compounds, including [[epigallocatechin gallate]] (EGCG), [[caffeine]], [[curcumin]], and [[resveratrol]], have also been reported to inhibit mTOR when applied to isolated cells in culture;<ref name=Beevers/><ref name="pmid20812900">{{cite journal | author = Zhou H, Luo Y, Huang S | title = Updates of mTOR inhibitors | journal = Anticancer Agents Med Chem | volume = 10 | issue = 7 | pages = 571–81 | year = 2010 | month = September | pmid = 20812900 | doi = }}</ref> however, there is as yet no evidence that these substances inhibit mTOR when taken as [[dietary supplements]]. Some (e.g. [[Temsirolimus]]) are beginning to be used in the treatment of cancer.<ref name="pmid17041628">{{cite journal | author = Easton JB, Houghton PJ | title = mTOR and cancer therapy | journal = Oncogene | volume = 25 | issue = 48 | pages = 6436–46 | year = 2006 | month = October | pmid = 17041628 | doi = 10.1038/sj.onc.1209886 | url = | issn = }}</ref><ref name="pmid16883305">{{cite journal | author = Faivre S, Kroemer G, Raymond E | title = Current development of mTOR inhibitors as anticancer agents | journal = Nat Rev Drug Discov | volume = 5 | issue = 8 | pages = 671–88 | year = 2006 | month = August | pmid = 16883305 | doi = 10.1038/nrd2062 | url = | issn = }}</ref> mTOR inhibitors may also be useful for treating several age-associated diseases.<ref name="pmid19805415">{{cite journal | author = Hasty P | title = Rapamycin: the cure for all that ails | journal = J Mol Cell Biol | volume = 2 | issue = 1 | pages = 17–9 | year = 2010 | month = February | pmid = 19805415 | doi = 10.1093/jmcb/mjp033 | url = | issn = }}</ref> | |||